The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study

Annals of the Rheumatic Diseases

Volumn 67, Issue 1, 2008, Pages 74-79

  Bernatsky, Sasha ^a   Joseph, L ^b   Boivin, J F ^a   Gordon, C ^c   Urowitz, M ^d   Gladman, D ^d   Fortin, P R ^d   Ginzler, E ^e   Bae, S C ^f   Barr, S ^g   Edworthy, S ^g   Isenberg, D ^h   Rahman, A ^h   Petri, M ⁱ   Alarcon G S ^j   Aranow, C ^k   Dooley, M A ^a   Rajan, R ^l   Senecal J L ^m   Zummer, M ⁿ   Manzi, S ^o   Ramsey Goldman, R ^p   Clarke, A E ^b   more..

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d SUNY Downstate Medical Center   (United States)

^e Hanyang University College of Medicine   (South Korea)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ The University of Alabama at Birmingham   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁿ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

^p V Building ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CALCULATION; CANCER REGISTRY; CANCER RISK; CASE STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ETHNICITY; FEMALE; GEOGRAPHY; HAZARD RATIO; HEART RATE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RISK FACTOR; SAMPLE; SCORING SYSTEM; SEX; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TOBACCO;

ADULT; AZATHIOPRINE; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK; TIME;

EID: 37749038302     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.069039     Document Type: Article

References (53)

1. Bernatsky S, Boivin J-F, Joseph L, Rajan R, Manzi S, Ginzler E, et al. An international cohort study of cancer in SLE. Arthritis Rheum 2005;52:1481-90.
2. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-9.
3. Bjornadal L, Lovstrom B, Yin L, Lundberg I, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71
4. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover RN, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
5. Casey TP. Azathioprine (Imuran) administration and the development of malignant lymphoma in NZB mice. Clin Exp Immunol 1968;3:305- 12.
6. Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int 2000;13(Suppl 1):S394-8.
7. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-16.
8. Nossent H, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000;39:969-78
9. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-7.
10. Takada K, Illei G, Boumpas D. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001;10:154-62.
11. Belmont HM, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment. Lupus 1997;4:104-8.
12. Boumpas DT, Austin 3rd HA, Vaughan EM, Klippel JH, Steinberg AD, Balow JE. Severe lupus nephritis: controlled trial of pulse methylprednisone versus two different regiments of pulse cyclophosphamide. Lancet 1992;340:741-4.
13. Austin H, Klippel J, Balow J, le Riche N, Steinberg A, Plotz P, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1998;41:751.
16. Mosca M, Ruiz-Inastorza G, Khamashta MA, Hughes GR. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001;1:1065-76.
17. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15.
18. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
19. Hoffman G, Kerr G, Leavitt R, Hallahan C, Lebovics R, Rottem M, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
20. Silman AJ, Petrie J, Hazleman B, Evans SJW. Lymphoproliferative cancer and other malignancy in patients with rheumatoid-arthritis treated with Azathioprine - a 20 year follow up study. Ann Rheum Dis 1988;47:988-92.
21. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
22. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
23. Allison P. Survival analysis using the SAS system. 97-98. Cary, North Carolina: SAS Institute, 2001
24. Gladman DD, Ginzler EM, Goldsmith CH, Fortin PR, Liang MH, Urowitz MB, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus [Congresses]. J Rheumatol 1992;19:1820-1.
25. Gladman D, Urowitz M, Goldsmith C, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
26. Ibañez D, Urowitz MB, Gladman DD. Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE. J Rheumatol 2005;32:824-7.
27. Strand V, Gladman DD, Isenberg DA, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
28. Vitali C, Bombardieri S. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
29. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
30. Sharpe C, Collet J-P, McNutt M, Belzile E, Boivin J-F, Hanley H. Nested case-control study of NSAIDS on breast cancer. Br J Cancer 2000;83:112-20.
31. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacguotte A, Koenig KL, Shore RE. Aspirin and lung cancer in women. Brit J Cancer 2002;87:49- 53.
32. Leung M. Analysis of a ten-year prospective cohort of multi-ethnic systemic lupus erythematosus patients - focussing on mortality, malignancy and organ damage [dissertation]. Birmingham, UK: University of Birmingham, 2001.
33. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: some antineoplastic and immunosuppressive agents. Volume 26. Lyon, France: International Agency for Research on Cancer, 1981: 47
34. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: International Agency for Research on Cancer, 1995 142, 195.
35. Bergh J Jonsson PE Glimelius B Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001;40:253-81.
36. Kimby E Brandt L Nygren P Glimelius B. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol 2001;40:224-30.
37. Boivin J-F, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Nat Cancer Inst 1995;87:732-41.
38. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-30.
39. Belsley DA, Kuh E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley & Sons, 1980.
40. Wacholder S, Gail M, Pee D. Selecting an efficient design for assessing exposure-disease relationships in an assembled cohort. Biometrics 1991;47:63-76.
41. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
42. Richiardi L, Forastiere F, Boffetta P, Simonato L, Merletti F. Effect of different approaches to treatment of smoking as a potential confounder in a case-control study on occupational exposures. Occ Environ Med 2005;62:101-4.
43. Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. Volume 2. Lyon, France: World Health Organization, 1987.
44. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.
45. Miettinen O. Design options in epidemiologic research - an update. Scand J Work Environ Health 1982;8:7-14.
46. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32:1753-7.
47. Ognenovski V, Marder W, Somers E, Johnston C, Farrehi J, Selvaggi S, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763-7.
48. Bernatsky S, Ramsey-Goldman R, Gordon C, Joseph L, Boivin J-F, Rajan R, et al. Factors associated with abnormal pap results in systemic lupus erythematosus (SLE). Rheumatology 2004; 43:1386-9.
49. Tam L, Chan A, Chan P, Chang A, Li E. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50:3619- 25.
50. Committee on Practice Bulletins - Gynecology. Cervical cytology screening (ACOG Practice Bulletin Number 45, August 2003). Obst Gynecol 2003;102:417-27.
51. Curtis RE, Boice JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. New England J Med 1992;326:1745-51.
52. Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. JNCI Cancer Spectrum 1994;86:1450-7.
53. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger J. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study. Am J Med 1987;83:1-9.